Biopharma
|
March 18, 2024
Fresenius Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate
Fresenius Kabi and Formycon have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab biosimilar to Stelara in Europe and Canada.